Cytoskeleton alterations in non-alcoholic fatty liver disease

Metabolism. 2022 Mar:128:155115. doi: 10.1016/j.metabol.2021.155115. Epub 2021 Dec 30.

Abstract

Background: Due to its extremely high prevalence and severity, non-alcoholic fatty liver disease (NALFD) is a serious health and economic concern worldwide. Developing effective methods of diagnosis and therapy demands a deeper understanding of its molecular basis. One of the strategies in such an endeavor is the analysis of alterations in the morphology of liver cells. Such alterations, widely reported in NAFLD patients and disease models, are related to the cytoskeleton. Therefore, the fate of the cytoskeleton components is useful to uncover the molecular basis of NAFLD, to further design innovative approaches for its diagnosis and therapy.

Main findings: Several cytoskeleton proteins are up-regulated in liver cells of NAFLD patients. Under pathological conditions, keratin 18 is released from hepatocytes and its detection in the blood emerges as a non-invasive diagnosis tool. α-Smooth muscle actin is up-regulated in hepatic stellate cells and its down-regulation has been widely tested as a potential NALFD therapeutic approach. Other cytoskeleton proteins, such as vimentin, are also up-regulated.

Conclusions: NAFLD progression involves alterations in expression levels of proteins that build the liver cytoskeleton or associate with it. These findings provide a timely opportunity of developing novel approaches for NAFLD diagnosis and therapy.

Keywords: Cytoskeleton; Hepatic stellate cells; Hepatocytes; Keratin 18; Non-alcoholic fatty liver disease; α-Smooth muscle actin.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Actins / metabolism
  • Animals
  • Cytoskeletal Proteins / metabolism*
  • Hepatic Stellate Cells / metabolism
  • Humans
  • Keratin-18 / metabolism
  • Liver / metabolism*
  • Non-alcoholic Fatty Liver Disease / diagnosis
  • Non-alcoholic Fatty Liver Disease / drug therapy
  • Non-alcoholic Fatty Liver Disease / metabolism*
  • Vimentin / metabolism

Substances

  • ACTA2 protein, human
  • Actins
  • Cytoskeletal Proteins
  • Keratin-18
  • Vimentin